Real|World Study Shows Patients Treated with IMBRUVICA ...

Real-World Study Shows Patients Treated with IMBRUVICA ...

More than two years of electronic medical records indicate patients were 89 percent more likely to start a next-line treatment when on ...

Real-World Analysis Shows Promising Outcomes, Safety With ...

A real-world analysis identified that ibrutinib (Imbruvica) remains a valuable treatment option for patients with chronic lymphocytic leukemia (CLL) due to its ...

Real-World Comparison of First-Line Treatment Adherence Between ...

In this real-world analysis, CLL/SLL patients initiating 1L once-daily ibrutinib had >50% higher treatment adherence than those initiating twice ...

Findings from landmark RESONATE-2 study confirm sustained ...

With up to ten years of follow-up, patients treated with ibrutinib demonstrated a significant and sustained progression-free survival (PFS) ...

Real-World Characteristics and Outcome of Patients Treated With ...

This real-world study shows that single-agent ibrutinib is an effective therapy for CLL, regardless of age and high-risk molecular features, consistent with ...

Study: Imbruvica for CLL Is Less Likely to Lead to Next-Line ...

Results show possible impact of using Janssen Pharmaceuticals' ibrutinib in the front-line setting, providing additional data on chronic ...

Results from a Real-World Multicenter Analysis of 482 Patients with ...

A previous study showed that patients who were treated with ibrutinib experienced frequent dose reductions and discontinuations. This study ...

Real-World Outcome of Treatment with Single-Agent Ibrutinib ... - MDPI

In clinical trials, ibrutinib was found to be effective and well-tolerated in patients with chronic lymphocytic leukemia (CLL). To confirm these findings, ...

Real-World Study Shows Patients Treated with IMBRUVICA ...

IMBRUVICA® is approved in more than 100 countries and has been used to treat more than 270,000 patients worldwide. There are more than 50 ...

Real-World Study Shows Patients Treated with IMBRUVICA ...

Real-World Study Shows Patients Treated with IMBRUVICA® (ibrutinib) Were Less Likely to Initiate a Next-Line Treatment than Patients on ...

Second-Gen BTKi Drugs Outperform Ibrutinib in CLL/SLL

Second-Gen BTKi Drugs Outperform Ibrutinib in CLL/SLL: Real-World Study Shows Promise for Acalabrutinib and Zanubrutinib ... treated patients with ...

Combined Data from Multiple Phase 3 Studies of IMBRUVICA ...

The weighted analysis showed that high-risk patients treated with IMBRUVICA had significantly longer median TTNT and were 54 percent less likely ...

Final results on effectiveness and safety of Ibrutinib in patients with ...

In a real-world multicenter retrospective study, conducted on 205 CLL patients treated with ibrutinib, the 12-months PFS and OS rates were ...

Ibrutinib improves diffuse large B-cell lymphoma survival - NCI

NCI researchers have found that adding the targeted therapy ibrutinib (Imbruvica) to standard chemotherapy can improve how long some younger ...

Real-World Persistence and Time to Next Treatment With Ibrutinib in ...

Consistent with our results, another analysis of electronic health record data from the Flatiron Health database showed that among 1037 patients with CLL/SLL ...

New Data Demonstrate Long-Term Benefit of IMBRUVICA ...

In this U.S. retrospective study, the largest of its kind to date, patients with high-risk CLL treated with single-agent IMBRUVICA® had ...

Long-term efficacy and safety of first-line ibrutinib treatment ... - Nature

Data previously reported from this study after a median follow-up of 28.5 months demonstrated a sustained PFS benefit for ibrutinib and improved ...

A retrospective observational study of ibrutinib in chronic ...

This is one of the largest cohorts of ibrutinib-treated patients in the world. The profile of CLL patients treated with ibrutinib was in ...

Real-world comparative effectiveness of acalabrutinib and ibrutinib ...

Consistent with those findings, this study found a lower proportion of treatment discontinuation in patients treated with acalabrutinib than in ...

Why Older Patients With CLL Stop Taking Ibrutinib

Real-world data published in a new report show that two-thirds of ... Among 89 patients in the study treated with liso-cel, occurrences ...